Marex Group: record earnings, but how much of 2026 is repeatable?

Marex has delivered six record quarters in a row since its 2024 listing, and the share price has roughly doubled in 2026. It is one of the highest-quality businesses in this series. The question is not quality. It is how much of 2026's volatility-driven earnings step-up will last.

At $71.59 on September 23, 2026, the shares trade 5.2% below my triangulated Base value of $75.55, an upside of 5.5%. The Bear value of $48.04 is 32.9% below the price, and the required margin of safety of 30% puts the maximum buy price at $52.89. For existing holders this is a hold. For new money it is a watchlist name.

Route: SF-01 adapted to a non-bank broker and market infrastructure platform. Economic classification: raw score 10/12, capped at Quality Growth because the listed history is short and a corporate cash flow model does not fit a broker. Primary method: normalized diluted EPS times a multiple. Secondary method: justified price to book. Values are present fair-value estimates, not 12-month price targets.

What Marex is

Marex is a diversified broker, clearer, market maker and hedging provider across energy, commodities and financial markets. It started as a commodities specialist and is broadening into prime services, equities, FX and market making, through both organic investment and acquisitions. It is not a deposit-taking bank, so bank metrics such as net interest margin do not apply, and generic free cash flow is not a meaningful anchor for a balance-sheet business.

The character of the business is changing moderately. Diversification is positive, but it raises integration and capital allocation risk. The company redomiciled to Bermuda in 2026, which changed its consolidated regulatory structure. New initiatives include Treasury cross-margining, prediction market clearing and a digital asset prime brokerage offering.

Results and growth

First-half 2026 adjusted profit before tax was $318.6 million, and adjusted return on equity 37.5%. In Q2 alone revenue rose 39% to $696 million, adjusted profit before tax 56% to $166 million and adjusted EPS 59% to $1.72. Management guided to the high end of its 10% to 20% growth range and expects acquisitions to contribute about a fifth of future growth.

Which earnings to value

Adjusted profit before tax is not capitalized directly. Of the $318.6 million, $236.9 million, or 74.4%, reached common shareholders as adjusted profit after tax, which gives the $3.13 of diluted EPS. Because acquisitions are part of the strategy, some adjusted exclusions recur, and the $500 million of hybrid perpetual capital issued in Q2 ranks ahead of common shareholders.

Annualizing the first half mechanically gives $6.26. The Base uses $6.00, a haircut for the exceptional activity in 2026. The Bear uses $5.20 and the Bull $6.75. Diluted shares of 75.6 million are about 5.1% above the basic count, so diluted EPS is used throughout.

Primary valuation: normalized EPS

The primary Base value is $6.00 at 13x, or $78.00. The Bear case pairs lower earnings with 10x, because weaker market activity would lower both earnings and confidence in their durability.

Secondary valuation: justified price to book

Common equity was $1,370.3 million at June 30, 2026, or $18.94 per share. Adding expected retained earnings for the second half, net of dividends, gives an estimated year-end book value of $21.49 per share in the Base case. Fair price to book is (ROE minus growth) / (cost of equity minus growth).

The Base case deliberately normalizes today's 37.5% ROE toward 24% to 27% rather than capitalizing it forever. The secondary Base value is $69.84.

Historical cross-check

Marex listed only in April 2024, so a five to ten year valuation history does not exist. At $71.59 the stock trades at 17.9x 2025 adjusted EPS, 11.4x annualized first-half EPS and 11.9x the $6.00 Base EPS. At the end of 2025 the shares traded around $39.

Valuation triangulation

The methods diverge by 11.0%, below the framework's 20% threshold, and the same weights apply in all three scenarios.

What is the market already pricing in?

At 13x, the price implies normalized EPS of $5.51, well below the $6.26 first-half run rate and below the $6.00 Base. On book value, the price implies sustainable ROE of about 26% at a 12% cost of equity and 6% growth. The market already assumes a meaningful normalization. Upside requires Marex to keep much of the 2026 step-up and to hold ROE far above its cost of equity.

Bear, base and bull scenarios

Bear: 2026 proves to be a volatility-driven peak, activity fades and the market applies a lower multiple to acquisition-heavy growth. Base: earnings settle modestly below the 2026 run rate and growth continues within guidance. Bull: most of the step-up holds, acquisitions compound and the premium multiple persists.

The probability-weighted value is $74.84, 4.5% above the price.

How the buy price is set

Confidence B starts at a 25% margin of safety. Five points are added for cyclicality, acquisition risk and model complexity, for a total of 30%. A 30% discount to the $75.55 Base gives a maximum buy price of $52.89. A 40% discount gives a stronger reference of $45.33.

Dividend

The quarterly dividend is $0.16, or $0.64 a year, a 0.9% yield. The dividend history since the 2024 listing is too short for a dividend framework, and income is secondary to reinvestment and per-share growth.

Reasons to own MRX

• High returns. Adjusted ROE above 35% in 2026, and above the cost of equity even after normalization.
• Per-share growth. Adjusted EPS rose from $2.31 in 2023 to $3.99 in 2025, and the first half of 2026 alone reached $3.13.
• Scalable infrastructure. Clearing connectivity, regulatory licenses and client relationships are hard to replicate.
• Diversification. Expansion beyond commodities reduces reliance on any one market.
• A price that already assumes normalization. At 13x, the market prices EPS of $5.51, below the Base.

What could go wrong?

• Earnings normalization. Earnings could fall sharply after exceptional 2026 volatility.
• Tail risks. Liquidity, counterparty and regulatory events can hit a clearing business hard and fast.
• Acquisitions. Integration problems or overpaying would destroy value.
• Operations and dilution. System failures and persistent dilution from share-based pay are ongoing risks.

Management execution

The company reports more than ten years of sequential growth in adjusted profit before tax. It beat guidance in 2024, grew adjusted profit before tax 30% in 2025 and reached $318.6 million in the first half of 2026. Recurring acquisitions make some adjusted exclusions less clean. Management credibility scores 16/20.

Stock Analyza scorecard

The valuation score is 60/100: the methods converge, but the discount to Base is small and the Bear value sits far below the price.

Confidence score

What I would watch from here

At June 30, 2026, liquidity headroom was $1,814.1 million and the internal group capital ratio 287%, both far from red. The next review point is Q3 2026 results.

The three most important thesis breakers

1. Normalized diluted EPS sustainably below about $5 without a credible recovery path.
2. A liquidity, counterparty or regulatory event at a clearing subsidiary.
3. A value-destroying acquisition or persistent dilution.

Adversarial review

The first draft set the Base at $78, equal to the primary method alone, although weighting the two methods gave $76.20. The framework does not allow the Base to be lifted to the higher method, so the weighted result is used. The draft's secondary value of $72 was stated without its inputs. It was rebuilt transparently from ROE, cost of equity, growth and expected book value, giving $69.84, and the same method was applied to Bear and Bull, which had previously used only the EPS method. The Base moved from $78.00 to $75.55, the maximum buy price from $54.60 to $52.89, and the Bear value from $52 to $48.04. The verdict is unchanged.

The strongest counter-argument is that 2026 is a volatility peak and acquisition-driven growth deserves a lower multiple. The Bear case captures that and lands well below the price, which is why this is a hold, not a buy.

Every test keeps the Base within about 11% of the price, and none lifts the buy price above about $56. The publication gate status is PASS_WITH_WARNING because of the short listed history and uncertain normalization.

Final verdict: hold at $71.59, watchlist for new money

Marex is a high-quality, fast-growing financial platform, but today's price lacks the downside protection the framework requires.

Verdict: HOLD at $71.59, WATCHLIST for new money. Triangulated Base value $75.55, upside 5.5%, Confidence B (19/25). Required margin of safety 30%, maximum buy price $52.89.

For an existing holder, quality and growth support holding. New money waits for $52.89 or below, or for evidence that the 2026 earnings level is durable.

The main thesis breaker is normalized diluted EPS sustainably below about $5 without a credible recovery path.

Sources

Primary sources include Marex's Q2 2026 earnings release, the 2025 Form 20-F, the full-year 2025 results, the full-year 2024 results and the Nasdaq redomiciliation notice. Market price history comes from a third-party market data aggregator.

The reference market price is $71.59, the regular session close on September 23, 2026. Balance sheet figures are as of June 30, 2026. Year-end book value is an estimate.